Article
The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.
British journal of clinical pharmacology - 1 Jan 2005
Hruska M W, Amico J A, Langaee T Y, Ferrell R E, Fitzgerald S M, Frye R F
Abstract excerpt
AIMS: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8. The anti-infective drug trimethoprim has been shown in vitro to be a selective inhibitor of CYP2C8. The purpose of this study was to evaluate the effect of trimethoprim on the CYP2C8 mediated metabolism of rosiglitazone in vivo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.